P135 (0160) BRENTUXIMAB-VEDOTIN + BENDAMUSTINE: A HIGHLY EFFECTIVE SALVAGE TREATMENT UN REFRACTORY/RELAPSED PATIENTS WITH HODGKIN LYMPHOMA
Format: | Article |
---|---|
Language: | English |
Published: |
Wiley
2018-10-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000547978.61156.2d |
Similar Items
-
P139 (0169) BRENTUXIMAB VEDOTIN ALONE AND IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY FOR PRIMARY REFRACTORY OR RELAPSED HODGKIN LYMPHOMA: MULTICENTRE EXPERIENCE OF THE POLISH LYMPHOMA RESEARCH GROUP
Published: (2018-10-01) -
TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01) -
COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01) -
P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
by: Swetha Kambhampati, et al.
Published: (2022-10-01) -
P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
by: Matthew Mei, et al.
Published: (2022-10-01)